Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: An IRMA 2 substudy

Diabetes

Volumn 55, Issue 12, 2006, Pages 3550-3555

  Persson, Frederik ^a   Rossing, Peter ^a   Hovind, Peter ^a   Stehouwer, Coen D A ^b   Schalkwijk, Casper ^b   Tarnow, Lise ^a   Parving, Hans Henrik ^a,c  

^a STENO DIABETES CENTER   (Denmark)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Faculty of Health Sciences   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IRBESARTAN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HUMAN; INFLAMMATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; TETRAZOLES;

EID: 33845523712     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-0827     Document Type: Article

References (40)

1. Parving H-H, Mauer M, Ritz E: Diabetic nephropathy. In Brenner and Rector's The Kidney: 7th edition. Brenner BM, Ed. WB Saunders, Boston, MA, 2004, p. 1777-1818
2. Strain WD, Chatarvedi N: The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst 3:243-246, 2002
3. Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S: The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 13:S173-S178, 2002
4. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
5. Lacourciere Y, Nadeau A, Poirier L, Tancrede G: Captopril or conventional therapy in hypertensive type II diabetics: three-year analysis. Hypertension 21:786-794, 1993
6. Agardh C-D, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 10:185-192, 1996
7. Stuveling EM, Bakker SJL, Hillege HL, de Jong PE, Gans ROB, de Zeeuw D: Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 20:497-508, 2005
8. Davis BJ, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H, Allen TJ, Cooper ME: Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47:89-97, 2004
9. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44:362-368, 2004
10. Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RAJM, Schalkwijk CG, IJzerman RG, Twisk JWR, Stehouwer CDA: Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 19:429-437, 2005
11. Fliser DM, Buchholz KM, Haller HM, the EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110:1103-1107, 2005
12. Tan K, Chow WS, Wong Y, Shiu S, Tam S: Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microabluminuria. Diabetes Care 25:1254-1255, 2002
13. Navalkar S, Parthasarathy S, Santanam N, Khan BV: Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 37:440-444, 2001
14. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274-3282, 2002
15. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H: Albuminuria and poor glycemic control predicts mortality in NIDDM. Diabetes 44:1303-1309, 1995
16. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med 157:1413-1418, 1997
17. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157-1165, 2002
18. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
19. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
20. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
21. Hofman W, Guder W: Preanalytical and analytical factors involved in the determination of urinary immunoglobin G, albumin, alpha 1-microglobin and retinol binding protein using the Behring nephelometer system. Lab Med 13:470-478, 1989
22. Seelig HP: [The Jaffe reaction with creatinine: reaction product and general reaction conditions]. Z Klin Chem Klin Biochem 7:581-585, 1969 [in German]
23. Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM: Glycated hemoglobin: methodologies and clinical applications. Clin Chem 32:B64-B70, 1986
24. Jager J, Kooy A, Lehert P, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD: Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 257:100-109, 2005
25. Wrobel K, Wrobel K, Garay-Sevilla M, Nava LE, Malacara JM: Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 43:1563-1569, 1997
26. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511, 2003
27. Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121-130, 1986
28. Ridker PM, Danielson E, Rifai N, Glynn RJ, the Val-MARC Investigators: Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC Trial. Hypertension 48:1-7, 2006
29. Brasier AR, Recinos A III, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22:1257-1266, 2002
30. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126, 1999
31. Libby P: Inflammation in atherosclerosis. Nature 420:868-874, 2002
32. Gasic S, Wagner OF, Fasching P, Ludwig C, Veitl M, Kapiotis S, Jilma B: Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 12:217-222, 1999
33. Andersen S, Schalkwijk CG, Stehouwer CD, Parving HH: Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care 23:1031-1032, 2000
34. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 38:635-638, 2005
35. Andersen S, van Nieuwenhoven FA, Tarnow L, Rossing P, Rossing K, Wieten L, Goldschmeding R, Parving HH: Reduction of urinary connective tissue growth factor by losartan in type 1 patients with diabetic nephropathy. Kidney Int 67:2325-2329, 2005
36. Pourdjabbar A, Lapointe N, Rouleau JL: Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes? Can J Cardiol 18 (Suppl. A):7A-14A, 2002
37. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P, the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352:29-38, 2005
38. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) Investigators: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20-28, 2005
39. de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S: Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 69:1675-1682, 2006
40. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Melhus H: The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 20:2089-2093, 2002